Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Prognostic factors and surgery in HPV-related oropharyngeal cancer

Marshall R. Posner, MD, The Tisch Cancer Institute, New York, NY, discusses current and potential prognostic factors for patients with human papillomavirus (HPV)-positive oropharyngeal cancer. Current research in biomarkers and HPV genotypes may predict patient outcomes more accurately. HPV69 is a rare subtype of HPV but is associated with a worse patient prognosis. Tobacco smoking additionally can affect patient prognostics, with smokers more likely to be excluded from de-escalation trials. Prof. Posner also discusses surgery in treating HPV-positive oropharyngeal cancer, which has the potential to reduce the need for radiotherapy, shown in the SIRS (NCT02072148) and E3311 (NCT01898494) trials. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Disclosures

Marshall R. Posner, MD has received consultancy feed from Merck (DMC), Kura (ad board), Hookipa (ad board), BioNtech (ad board), and Naveris (ad board).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.